文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

COVID-19与细菌性医疗保健相关感染的交叉领域

The interface between COVID-19 and bacterial healthcare-associated infections.
PubMed 文献 · Clin Microbiol Infect · 2021-06-07

该综述检索PubMed文献,探讨COVID-19患者中医院获得性细菌感染(包括耐药菌)的发生情况。部分医院报告产新德里金属β-内酰胺酶碳青霉烯耐药肠杆菌和碳青霉烯耐药鲍曼不动杆菌发生率较疫情前增加,而MRSA和VRE病例减少,后者归因于强化感染防控措施。耐药菌感染与更差结局相关,需进一步研究疫情后感染防控协议的成本效益及广谱抗生素长期影响。

要点

  • 重症COVID-19患者住院后可发生医院获得性耐药菌感染,与更差结局相关。
  • 部分医院报告NDM-CRE和CR-Ab发生率较疫情前增加。
  • MRSA和VRE病例减少,归因于强化感染防控措施。

核心结论

  • COVID-19患者可发生医院获得性细菌感染,包括多种耐药菌,且耐药菌感染与更差结局相关。

研究设计与样本

  • 综述:使用PubMed检索,检索词包括COVID-19、SARS-CoV-2、细菌感染、医疗保健相关感染、抗生素耐药等。

主要发现

  • 在COVID-19患者中引起医疗保健相关感染的耐药病原体包括MRSA、NDM-CRE、CR-Ab、ESBL-KP和VRE。
  • 部分医院报告NDM-CRE和CR-Ab发生率较疫情前增加。
  • 其他研究报告MRSA和VRE病例减少,归因于强化感染防控措施。
  • 住院COVID-19患者合并抗生素耐药感染时观察到更差结局。

关键数值与推荐

  • 推荐指南讨论COVID-19患者治疗中的抗菌药物管理,以最小化经验性广谱抗生素使用。

临床怎么用

  • 在COVID-19患者中应推行抗菌药物管理,减少经验性广谱抗生素使用。
  • 维持感染防控措施可能有助于减少某些医疗保健相关感染。

局限性

  • 需进一步研究确定疫情后维持COVID-19相关感染防控协议的成本效益关系。
  • 需评估疫情期间某些广谱抗生素高使用的长期影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A wide range of bacterial infections occur in coronavirus disease 2019 (COVID-19) patients, particularly in those with severe coronaviral disease. Some of these are community-acquired co-infections. OBJECTIVE: To review recent data that indicate the occurrence of hospital-onset bacterial infections, including with antibiotic-resistant isolates, in COVID-19 patients. SOURCES: Using PubMed, the literature was searched using terms including: 'COVID-19'; 'SARS-CoV-2'; 'bacterial infection'; 'healthcare-associated infection'; 'antibiotic resistance'; 'antimicrobial resistance'; 'multi-drug resistance'; 'Streptococcus'; 'Staphylococcus'; 'Pseudomonas'; 'Escherichia'; 'Klebsiella'; 'Enterococcus'; 'Acinetobacter'; 'Haemophilus'; 'MRSA'; 'VRE'; 'ESBL'; 'NDM-CRE'; 'CR-Ab'; 'VRSA'; 'MDR'. CONTENT: There is a growing number of reports of bacterial infections acquired by patients with severe COVID-19 after hospital admission. Antibiotic-resistant pathogens found to cause healthcare-associated infections (HAIs) in COVID-19 patients include methicillin-resistant Staphylococcus aureus, New Delhi metallo-β-lactamase-producing carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii, extended-spectrum β-lactamase Klebsiella pneumoniae and vancomycin-resistant enterococci. COVID-19 has impacted bacterial HAIs in a number of ways with an increase in the incidence of New Delhi metallo-β-lactamase-producing carbapenem-resistant Enterobacterales and carbapenem-resistant A. baumannii reported at some hospital sites compared with before the pandemic. Recommended guidelines for antimicrobial stewardship in COVID-19 patient treatment are discussed regarding minimization of empiric broad-spectrum antibiotic use. Other studies have reported a decrease in methicillin-resistant S. aureus and vancomycin-resistant enterococci cases, which has been attributed to enhanced infection prevention and control practices introduced to minimize intra-hospital spread of COVID-19. IMPLICATIONS: Poorer outcomes have been observed in hospitalized COVID-19 patients with an antibiotic-resistant infection. Although heightened IPC measures have been accompanied by a reduction in some HAIs at specific sites, in other situations, COVID-19 has been associated with an increase in bacterial HAI incidence. Further research is needed to define the cost-benefit relationship of maintaining COVID-19-related infection prevention and control protocols beyond the pandemic to reduce the burden of HAIs. In addition, the longer-term impact of high usage of certain broad-spectrum antibiotics during the COVID-19 pandemic requires evaluation.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. O'Toole RF. The interface between COVID-19 and bacterial healthcare-associated infections. Clin Microbiol Infect. 2021. PMID: 34111586. doi:10.1016/j.cmi.2021.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。